RAD21 and breast cancer: This study reveals significant differences in the genomic landscape between MMR-altered and MMR-wt breast cancers, as TP53 mutation, PTEN mutations, NF1 mutations, MYC amplification, RAD21 amplification, and RECQL4 amplification were enriched in MMR-altered breast cancers.